0001933414-24-000029.txt : 20240614 0001933414-24-000029.hdr.sgml : 20240614 20240614181549 ACCESSION NUMBER: 0001933414-24-000029 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240612 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Congleton Jon CENTRAL INDEX KEY: 0001644975 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41614 FILM NUMBER: 241046362 MAIL ADDRESS: STREET 1: 3122 STERLING CIRCLE, SUITE 200 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc. CENTRAL INDEX KEY: 0001933414 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: (888) 378-6240 MAIL ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 4 1 wk-form4_1718403341.xml FORM 4 X0508 4 2024-06-12 0 0001933414 Mineralys Therapeutics, Inc. MLYS 0001644975 Congleton Jon 150 N. RADNOR CHESTER ROAD, SUITE F200 RADNOR PA 19087 1 1 0 0 Chief Executive Officer 1 Common Stock 2024-06-12 4 S 0 16607 12.7665 D 1032461 D Common Stock 2024-06-13 4 S 0 39961 12.7381 D 992500 D Common Stock 2024-06-14 4 S 0 16229 12.5185 D 976271 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.4587 to $13.35. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.49 to $13.04. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.635. /s/ Adam Levy, Attorney-in-fact 2024-06-14